WBB Securities Starts ContraFect Corp. (CFRX) at Speculative Buy

March 31, 2021 10:35 AM EDT
Get Alerts CFRX Hot Sheet
Price: $4.23 +7.63%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 5 | New: 41
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

WBB Securities analyst Steve Brozak initiates coverage on ContraFect Corp. (NASDAQ: CFRX) with a Speculative Buy rating and a price target of $6.50.

The analyst commented, "Though the COVID-19 pandemic has received most attention during the past year, it is imperative that the medical R&D community continue to devote efforts to developing new treatments for AMR infections. We believe the CFRX research and development pipeline represents a crucial medical advancement that can reverse the growing threat of bacterial resistance to the currently available standard-of-care (SOC) antibiotics that key opinion leaders have said could force medicine to retreat to a pre-penicillin era. We are therefore initiating coverage of CFRX with a Speculative Buy rating and a 12-month price target of $6.50."

For an analyst ratings summary and ratings history on ContraFect Corp. click here. For more ratings news on ContraFect Corp. click here.

Shares of ContraFect Corp. closed at $4.48 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage